<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30159" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Papillary Thyroid Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Limaiem</surname>
            <given-names>Faten</given-names>
          </name>
          <aff>University of Tunis El Manar, Tunis Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Anis</given-names>
          </name>
          <aff>District Endocrine/Sentara Northern Virginia Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mazzoni</surname>
            <given-names>Thomas</given-names>
          </name>
          <aff>Cooperman Barnabas Medical Center/Rutgers University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faten Limaiem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anis Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Mazzoni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30159.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Papillary thyroid carcinoma (PTC) is an epithelial malignancy showing evidence of follicular cell differentiation and distinctive nuclear features. It is the most frequent thyroid neoplasm and carries the best overall prognosis. The tumor usually appears as an irregular thyroid solid mass, but it may have cystic features in rare cases. One key feature of PTC is its ability to invade adjacent structures like lymphatics. About 10% of patients may present with metastatic disease at initial presentation. The overall prognosis is good for most patients, especially the ones younger than 45 years of age. This activity illustrates the role of the interprofessional team in diagnosing and managing patients with papillary cancer of the thyroid.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the risk factors associated with the development of papillary thyroid cancer.</p></list-item><list-item><p>Identify&#x000a0;the different features seen in the histopathology report of a biopsy in a patient with papillary thyroid cancer.</p></list-item><list-item><p>Assess&#x000a0;the different treatment choices for papillary thyroid cancer based on tumor size and other clinical features.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30159&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30159">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30159.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Papillary thyroid carcinoma (PTC) is an epithelial malignancy showing evidence of follicular cell differentiation and distinctive nuclear features.&#x000a0;It is the most frequent thyroid neoplasm&#x000a0;and carries the best overall prognosis. The tumor usually appears as an irregular solid mass but may have cystic features in rare cases. One key feature of PTC is its ability to invade adjacent structures like lymphatics. About 10% of patients may present with metastatic disease at initial presentation. The overall prognosis is good for most patients, especially the ones younger than 45 years of age.</p>
      </sec>
      <sec id="article-30159.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Known risk factors for PTC include:</p>
        <p>
<bold>Radiation Exposure</bold>
</p>
        <p>The incidence of papillary thyroid cancer is greater in people with a history of exposure to significant ionizing radiation.&#x000a0;</p>
        <p>
<bold>Childhood Exposure</bold>
</p>
        <p>External low-dose radiation therapy to the head and neck during childhood, used in the 1940s to 1960s to treat various benign diseases, predisposes to PTC. The average time from irradiation to tumor recognition is approximately&#x000a0;10 years but may be longer than 30 years.<xref ref-type="bibr" rid="article-30159.r1">[1]</xref>
<bold>Medical Therapy</bold></p>
        <p>High radiation doses (&#x0003e;&#x000a0;2000&#x000a0;cGy) used in treating malignant diseases&#x000a0;have&#x000a0;also been associated with an increased risk of PTC. <bold>Environmental Exposure</bold></p>
        <p>The Chornobyl nuclear accident, which occurred on April 26, 1986, led to a 3- to 75-fold increase in the incidence of PTC in fallout regions, especially in younger children.</p>
        <p>
<bold>Genetics</bold>
</p>
        <p>A few familial syndromes are associated with PTC, including familial adenomatous polyposis&#x02014;Gardner syndrome, Werner syndrome, and Carney complex type 1. Familial PTC cases have been reported in 5% of all patients with PTC and may portend a more aggressive disease course.<xref ref-type="bibr" rid="article-30159.r2">[2]</xref></p>
        <p>
<bold>Other</bold>
</p>
        <p>PTC is higher in regions with high dietary iodine intake&#x000a0;and patients with preexisting benign thyroid disease.<xref ref-type="bibr" rid="article-30159.r3">[3]</xref>&#x000a0;There is also a trend for an increased incidence of thyroid cancer due to being overweight&#x000a0;or obese, as shown in a report studying the changes in the frequency of thyroid cancer between 1995 and 2015.<xref ref-type="bibr" rid="article-30159.r4">[4]</xref></p>
      </sec>
      <sec id="article-30159.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PTC&#x000a0;is the predominant form of thyroid cancer, accounting for 80&#x000a0;to 85% of all thyroid cancer cases. In a report based on the Surveillance, Epidemiology, and End Results (SEER) database from 1975 to 2012, the incidence of PTC increased from 4.8 to 14.9 per 100,000.<xref ref-type="bibr" rid="article-30159.r5">[5]</xref><xref ref-type="bibr" rid="article-30159.r6">[6]</xref><xref ref-type="bibr" rid="article-30159.r7">[7]</xref>&#x000a0;A recent report of autopsy results showed no difference in the prevalence of subclinical thyroid cancer through lifespan and different age groups.<xref ref-type="bibr" rid="article-30159.r8">[8]</xref>&#x000a0;One of the latest thoughts in the medical community is that there is an obvious overdiagnosis of thyroid cancer in general that might even result in overtreatment&#x000a0;without necessarily changing the ultimate prognosis and mortality from the disease.<xref ref-type="bibr" rid="article-30159.r9">[9]</xref>&#x000a0;The overdiagnosis is usually due to frequent incidental finding of microcancers of the thyroid gland in routine imaging studies, and the overtreatment is due to the slow-changing mentality of the medical force that is still using aggressive surgical therapy as definite treatment of thyroid cancer versus the newest more conservative approach of observation or more limited surgical intervention. PTC&#x000a0;occurs predominantly in middle-aged adults with a 3&#x000a0;to 1 female-to-male ratio; the median age at presentation is 50 years. Even though rare in children, PTC is still the most common pediatric thyroid malignancy. It affects Whites more commonly than Blacks.<xref ref-type="bibr" rid="article-30159.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30159.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Chromosomal rearrangements have been identified in PTC, including the RET protooncogene, NTRK1, and MET gene overexpression.<xref ref-type="bibr" rid="article-30159.r11">[11]</xref> Further, mutations in the BRAF gene have also been identified and correlated with prognosis, particularly BRAFV600E mutation.<xref ref-type="bibr" rid="article-30159.r12">[12]</xref><xref ref-type="bibr" rid="article-30159.r13">[13]</xref><xref ref-type="bibr" rid="article-30159.r14">[14]</xref><xref ref-type="bibr" rid="article-30159.r15">[15]</xref>&#x000a0;A clear association between PTC and radiation exposure is now well established.</p>
      </sec>
      <sec id="article-30159.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Gross Findings</bold>
</p>
        <p>Grossly, PTC typically presents as an invasive neoplasm with poorly defined margins, a firm consistency, and a granular white-cut surface. Calcifications may be present. The size is widely variable, with a mean diameter of 2-3 cm.&#x000a0;PTC has&#x000a0;3 classification categories based on the size and extent of the primary lesion. Minimal carcinoma or occult carcinoma/micro-carcinoma tumors are 1.5 cm or smaller and show no evidence of invasiveness through the thyroid capsule or cervical lymph nodes. These lesions are typically nonpalpable and usually found as incidental findings during operative or autopsy examination. Intra-thyroid tumors are greater than 1.5 cm in diameter but remain confined to the thyroid gland with no evidence of extra-thyroid invasion. Extra-thyroid&#x000a0;tumors extend through the thyroid capsule to involve the surrounding viscera.<xref ref-type="bibr" rid="article-30159.r16">[16]</xref></p>
        <p>
<bold>Microscopic Findings</bold>
</p>
        <p>The&#x000a0;2 cardinal morphological features of conventional PTC are the papillae and the nuclear changes. The papillae comprise a central fibrovascular stalk covered by a neoplastic epithelial lining. The papillae may be long, straight, or arborizing, arranged in a parallel, regimented fashion, short and stubby, or tightly packed. The thickness and composition of the papillary stalk are variable. The stalk usually comprises loose connective tissue and variously sized thin-walled vessels.<xref ref-type="bibr" rid="article-30159.r17">[17]</xref>&#x000a0;The diagnosis of papillary carcinoma is based on the nuclear morphology of a thyroid neoplasm (see <bold>Image.</bold> Papillary&#x000a0;Thyroid&#x000a0;Carcinoma, FNA Giemsa Stain). The existence of multiple architectural variants proves the irrelevance of architecture.<xref ref-type="bibr" rid="article-30159.r17">[17]</xref> The following constellation of features characterizes the diagnostic nuclear morphology:</p>
        <list list-type="order">
          <list-item>
            <p>Enlarged and elongated nuclei with crowding and overlap</p>
          </list-item>
          <list-item>
            <p>Irregular nuclear contour</p>
          </list-item>
          <list-item>
            <p>Chromatin clearing with peripheral margination of chromatin, giving rise to what has been described as Orphan Annie Eye nuclei</p>
          </list-item>
          <list-item>
            <p>Multiple micro-nucleoli located immediately underneath the nuclear membrane</p>
          </list-item>
          <list-item>
            <p>Nuclear grooves resulting from an irregularity of nuclear contour seen in 2 dimensions</p>
          </list-item>
          <list-item>
            <p>Intranuclear cytoplasmic pseudo-inclusions from the accumulation of cytoplasm in prominent nuclear grooves</p>
          </list-item>
          <list-item>
            <p>Presence of psammoma bodies</p>
          </list-item>
        </list>
        <p>
<bold>Immunohistochemical Findings</bold>
</p>
        <p>Immunohistochemistry is seldom of value in diagnosing PTC, although it may play a role in metastatic disease. The neoplastic cells are strongly and diffusely immunoreactive with keratin, CK7, thyroglobulin, TTF1, and PAX8, while other markers (HBME-1, Galectin-3, S100 protein, CITED1, CK19) yield variable results.<xref ref-type="bibr" rid="article-30159.r18">[18]</xref></p>
      </sec>
      <sec id="article-30159.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PTC&#x000a0;usually presents as an asymptomatic (painless) thyroid mass with or without enlargement of regional (cervical) lymph nodes. Hoarseness and dysphagia occur in approximately 20% of cases, signaling recurrent laryngeal nerve involvement with vocal cord paralysis or tracheal compression. Nodal metastases in the lateral neck&#x000a0;are reported&#x000a0;in 27% of patients at presentation, most often originating from tumors in the ipsilateral thyroid lobe.<xref ref-type="bibr" rid="article-30159.r19">[19]</xref>&#x000a0;In rare cases, there could be lateral lymph node involvement.<xref ref-type="bibr" rid="article-30159.r20">[20]</xref>&#x000a0;The examination reveals a painless hard lesion, usually less than 5 cm. The mass is often fixed and has irregular borders.</p>
      </sec>
      <sec id="article-30159.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Fine Needle Aspiration (FNA)</bold>
</p>
        <p>It is frequently the initial diagnostic method used in&#x000a0;the detection of PTC.&#x000a0;Fine-needle aspiration specimens from conventional PTC are usually cellular. They may show papillary structures, monolayer sheets, and 3D groups in a background of watery or thick so-called ropy colloid, nuclear or calcific debris, macrophages, and stromal fragments. The individual tumor cells with eosinophilic cytoplasm are enlarged, elongated, or oval. The nuclei show elongation, membrane thickening, chromatin clearing, grooves, and pseudo-inclusions.&#x000a0;These tumors usually show enlarged follicular cells arranged in monolayer sheets and follicular groups in a thin and thick colloid background.<xref ref-type="bibr" rid="article-30159.r21">[21]</xref><xref ref-type="bibr" rid="article-30159.r22">[22]</xref></p>
        <p>
<bold>Laboratory Tests</bold>
</p>
        <p>Thyroid function testing has limited utility in diagnosing PTC because most patients have normal thyroid function.<xref ref-type="bibr" rid="article-30159.r23">[23]</xref></p>
        <p>
<bold>Radiographic Features</bold>
</p>
        <p>On thyroid scans, PTCs typically appear as cold (hypo-functioning) nodules but rarely can appear as hot (hyperfunctioning) nodules. Ultrasound examination is the imaging modality of choice for PTC. Sonographic features include a hypoechoic or isoechoic solid nodule with irregular or poorly defined margins, micro-calcifications, taller-than-wide shape, and disorganized internal vascularity. Ultrasound findings are also invaluable for guiding fine-needle aspiration biopsy of abnormal nodes. Microcalcifications are highly specific for this type of cancer. Other imaging modalities, including CT, MRI, and&#x000a0;FDG-PET/CT, may&#x000a0;be needed to assess the extent of extra-thyroidal extension, evaluate the presence of&#x000a0;substernal masses, detect recurrent tumors, and improve diagnostic accuracy.<xref ref-type="bibr" rid="article-30159.r24">[24]</xref></p>
      </sec>
      <sec id="article-30159.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Surgery</bold>
</p>
        <p>Primary treatment decisions have as their basis a preoperative risk assessment that includes clinical, imaging, and cytological data.<xref ref-type="bibr" rid="article-30159.r25">[25]</xref> Choices depend on the location and extent of identifiable disease and the risk that unidentifiable disease foci are also present. With increasing emphasis on risk-stratified management, the treatment approaches recommended by the 2015 ATA guidelines are more conservative than in the past.<xref ref-type="bibr" rid="article-30159.r26">[26]</xref><xref ref-type="bibr" rid="article-30159.r27">[27]</xref><xref ref-type="bibr" rid="article-30159.r28">[28]</xref>&#x000a0;Small-size papillary cancers can be followed conservatively with active surveillance and without any intervention, and surgery can be pursued only if there is a significant change in size or internal features of the tumor.<xref ref-type="bibr" rid="article-30159.r29">[29]</xref><xref ref-type="bibr" rid="article-30159.r30">[30]</xref>&#x000a0;A recent study showed that there is still an adjustment period among physicians who are still recommending more aggressive treatment choices despite the current changes.<xref ref-type="bibr" rid="article-30159.r31">[31]</xref><xref ref-type="bibr" rid="article-30159.r32">[32]</xref></p>
        <p>A lobectomy is an option for unifocal tumors smaller than 4 cm with no evidence of extrathyroidal extension or lymph node metastasis. For patients with PTC &#x0003e;4 cm, or with gross extra-thyroidal extension (clinical T4), or clinically apparent metastatic disease to nodes (clinical N1) or distant sites (clinical M1), the initial surgical procedure should include a near-total or total thyroidectomy and gross removal of all primary tumor unless there are contraindications to this procedure. If surgery is chosen for patients with thyroid cancer &#x0003c;1 cm without extra-thyroidal extension and cN0, the initial surgical procedure should be a thyroid lobectomy unless there are clear indications to remove the contralateral lobe. Thyroid lobectomy alone is sufficient treatment for small, unifocal, intrathyroidal carcinomas in the absence of prior head and neck radiation, familial thyroid carcinoma, or clinically detectable cervical nodal metastases.<xref ref-type="bibr" rid="article-30159.r26">[26]</xref><xref ref-type="bibr" rid="article-30159.r33">[33]</xref>&#x000a0;Prophylactic central-compartment neck dissection (ipsilateral or bilateral) should be considered in patients with PTC with clinically uninvolved central neck lymph nodes (cN0) who have advanced primary tumors (T3 or T4) or clinically involved lateral neck nodes (cN1b) or if the information be used to&#x000a0;plan further steps in therapy.</p>
        <p>
<bold>Adjuvant Radioiodine Therapy</bold>
</p>
        <p>After thyroidectomy, radioiodine&#x000a0;is the therapy of choice in patients with PTC to ablate residual normal thyroid tissue.&#x000a0;</p>
        <p>Radioiodine therapy&#x000a0;is indicated in several cases.<xref ref-type="bibr" rid="article-30159.r34">[34]</xref>&#x000a0;These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with a tumor &#x0003e;2 cm and&#x000a0;1 of the following risk factors: gross extra-thyroidal extension, age &#x0003e; 45 years, lymph node and distant metastases</p>
          </list-item>
          <list-item>
            <p>Patients with a tumor &#x0003c;2 cm and distant metastasis</p>
          </list-item>
        </list>
        <p>Radioactive iodine therapy is given 4&#x000a0;to 6 weeks after surgery. Before treatment, a hypothyroid state is induced by stopping thyroid hormone replacement treatment. The therapy is continued until no more radioactive iodine uptake is seen. Potential adverse effects of radioactive iodine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sialoadenitis</p>
          </list-item>
          <list-item>
            <p>Transient thyrotoxicosis</p>
          </list-item>
          <list-item>
            <p>Pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Emesis</p>
          </list-item>
          <list-item>
            <p>Brain edema (can be prevented with the use of corticosteroids)</p>
          </list-item>
          <list-item>
            <p>Infertility</p>
          </list-item>
          <list-item>
            <p>There is a small risk of leukemia, breast or bladder cancer</p>
          </list-item>
        </list>
        <p>Thyroid Hormone Treatment</p>
        <p>After thyroidectomy, patients&#x000a0;require lifelong thyroid hormone therapy, usually as monotherapy with levothyroxine (LT4). Since TSH can promote the growth of remaining PTC cells, the dosage of LT4 should initially be high enough to achieve suppression of thyrotropin. The thyroid function should be checked after 6 to 8 weeks. Depending on the result,&#x000a0;the dosage should be adjusted; the use of TSH suppressive therapy should merit careful consideration since it carries an increased risk of complications.<xref ref-type="bibr" rid="article-30159.r26">[26]</xref></p>
        <p>
<bold>NCCN Guidelines for Total Thyroidectomy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Known distant metastases</p>
          </list-item>
          <list-item>
            <p>History of radiation</p>
          </list-item>
          <list-item>
            <p>Extrathyroidal extension</p>
          </list-item>
          <list-item>
            <p>Bilateral nodules</p>
          </list-item>
          <list-item>
            <p>The tumor measures more than 4 cm</p>
          </list-item>
          <list-item>
            <p>Poorly differentiate lesion</p>
          </list-item>
          <list-item>
            <p>Positive cervical lymph nodes</p>
          </list-item>
        </list>
        <p>Routine cervical node dissection continues to be debated. Some literature notes fewer recurrences, but other studies have noted a higher incidence of recurrent nerve injury.</p>
        <p>
<bold>New Developments</bold>
</p>
        <p>New techniques have been tried for initially treating smaller-size papillary thyroid cancer with good results, like thermal ablation&#x000a0;and ultrasound radiofrequency ablation for treating recurrent disease.<xref ref-type="bibr" rid="article-30159.r35">[35]</xref><xref ref-type="bibr" rid="article-30159.r36">[36]</xref>&#x000a0;</p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>This is reserved for patients with recurrent or excessive remnant disease after the initial surgical treatment and radioactive iodine ablation. The most common agents used are the kinase inhibitors that target different pathways, like the anti-angiogenic multi-targeted kinase inhibitors (aaMKI- lenvatinib, sorafenib), BRAF kinase inhibitors (vemurafenib, dabrafenib), MEK inhibitors (trametinib, cobimetinib), NTR kinase inhibitors (larotrectinib), and RET inhibitors (selpercatinib).<xref ref-type="bibr" rid="article-30159.r37">[37]</xref><xref ref-type="bibr" rid="article-30159.r38">[38]</xref><xref ref-type="bibr" rid="article-30159.r39">[39]</xref></p>
      </sec>
      <sec id="article-30159.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The primary differential diagnoses of PTC&#x000a0;are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Reactive changes following fine-needle aspiration.<xref ref-type="bibr" rid="article-30159.r40">[40]</xref> This&#x000a0;condition characteristically shows nuclear enlargement, chromatin clearing, and micro-nucleoli similar to the nuclei of PTC.</p>
          </list-item>
          <list-item>
            <p>Severe chronic lymphocytic thyroiditis, where the reactive atypia is attributed to inflammation, results in nuclear morphology similar to that of PTC.<xref ref-type="bibr" rid="article-30159.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Adenomatoid&#x000a0;nodules</p>
          </list-item>
          <list-item>
            <p>Diffuse hyperplasia</p>
          </list-item>
          <list-item>
            <p>Dyshormonogenetic&#x000a0;goiter</p>
          </list-item>
          <list-item>
            <p>Follicular adenoma</p>
          </list-item>
          <list-item>
            <p>Follicular thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Medullary thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Metastatic tumors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30159.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Several staging systems have been proposed for PTC and continue to evolve.<xref ref-type="bibr" rid="article-30159.r42">[42]</xref><xref ref-type="bibr" rid="article-30159.r43">[43]</xref>&#x000a0;The most commonly used are:</p>
        <p>For patients less than 45 years:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage l: any Tm, any N, M0 (cancer localized to the thyroid)</p>
          </list-item>
          <list-item>
            <p>Stage ll: Any T, any N, M1 (cancer spread to cervical nodes or distant organs)</p>
          </list-item>
        </list>
        <p>For patients older than 45 years:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage l: T1, N0, M0 (cancer less than 2 cm)</p>
          </list-item>
          <list-item>
            <p>Stage ll: T2, N0, M0, and T3 (cancer localized to the thyroid that is between 2&#x000a0;to 4 cm)</p>
          </list-item>
          <list-item>
            <p>Stage lll: T4, N0, M0, and any T, N1, M0 (lesion more than 4 cm and spread limited to the neck)</p>
          </list-item>
          <list-item>
            <p>Stage lV: Any T, any N, M1 (cancer spread outside the neck and to distant organs)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30159.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Although PTC frequently metastasizes to regional lymph nodes, it generally carries an excellent prognosis. There are, however, several clinicopathological and background features that can lead to a poor prognosis.<xref ref-type="bibr" rid="article-30159.r44">[44]</xref><xref ref-type="bibr" rid="article-30159.r45">[45]</xref><xref ref-type="bibr" rid="article-30159.r46">[46]</xref><xref ref-type="bibr" rid="article-30159.r47">[47]</xref></p>
        <p>Poor prognostic factors of PTC include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Older age at diagnosis</p>
          </list-item>
          <list-item>
            <p>Large tumor size</p>
          </list-item>
          <list-item>
            <p>Extra-thyroidal&#x000a0;growth</p>
          </list-item>
          <list-item>
            <p>Male sex</p>
          </list-item>
          <list-item>
            <p>Less differentiated or solid areas, vascular invasion, and aneuploid cell population</p>
          </list-item>
          <list-item>
            <p>Subtypes of&#x000a0;PTC that are associated with&#x000a0;a more aggressive clinical behavior like the tall cell variant, a diffuse sclerosis variant, the solid variant, and the follicular variant</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30159.s13" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Extra-thyroidal Extension</bold>
</p>
        <p>Extra-thyroidal extension occurs in 8% to 32% of the cases.<xref ref-type="bibr" rid="article-30159.r48">[48]</xref></p>
        <p>
<bold>Local or Regional Recurrences</bold>
</p>
        <p>Local or regional recurrences occur in 5 to 15% of patients with PTC.<xref ref-type="bibr" rid="article-30159.r49">[49]</xref></p>
        <p>
<bold>Distant Metastases</bold>
</p>
        <p>Distant metastasis occurs in only 1% to 25%, mainly in the lungs and bones. Other less common sites are the brain, liver, and skin.<xref ref-type="bibr" rid="article-30159.r50">[50]</xref></p>
      </sec>
      <sec id="article-30159.s14" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Long-term monitoring is necessary every 6&#x000a0;to 12 months for at least 5 years and annually thereafter to look for recurrence. During those visits, TSH, thyroglobulin, and antithyroglobulin antibodies should be measured.</p>
      </sec>
      <sec id="article-30159.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients need to know the extent of the thyroid cancer, as well as the appropriate follow-up routine. Reassurance should be offered about the ultimate good prognosis so patients feel less stressed and avoid the stigma of cancer.</p>
      </sec>
      <sec id="article-30159.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Papillary thyroid cancer is ideally managed&#x000a0;by an interprofessional team that consists of an endocrinologist, general surgeon, oncologist, radiation oncologist, nuclear medicine clinician, internist, pharmacist (oncology or nuclear medicine specialized), and specialty care nurse. Most patients present to the primary care provider or nurse practitioner with a painless mass in the neck. Once the FNA is performed, the patient should be referred to an endocrinologist and a surgeon. Patients need to know that the sole treatment for PTC is surgery. Patients treated with radioactive iodine need to be educated about this therapy and warned about the potential adverse effects. Following surgery, all patients require long-term monitoring for recurrence. Most patients require long-term thyroid hormone replacement. Specialty care nurses in endocrinology or oncology assist with treatment, monitor and educate patients, and provide updates to the team. Pharmacists assist with nuclear medicine and chemotherapy, as well as hormone replacement therapy following treatment measures. Best practices require open communication among all team members, particularly if they note a change or deterioration in the patient's condition. This includes accurate and updated patient records so everyone involved in care can access the latest patient data. This interprofessional care model yields the best patient results. With early diagnosis and prompt treatment, the prognosis for most patients with PTC is excellent.</p>
      </sec>
      <sec id="article-30159.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30159&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30159">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/papillary-thyroid-carcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30159">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30159/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30159">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30159.s18">
        <fig id="article-30159.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Papillary Thyroid Carcinoma, FNA Giemsa Stain. Ed Uthman, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/wiki/File:Papillary_Thyroid_Carcinoma,_FNA,_Giemsa_Stain_(7782080838).jpg">Public Domain</ext-link>, via Wikimedia Commons&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="800px-Papillary_Thyroid_Carcinomax_FNAx_Giemsa_Stain_x7782080838x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30159.s19">
        <title>References</title>
        <ref id="article-30159.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and treatment of thyroid cancer in children and adolescents: a retrospective analysis of 83 patients.</article-title>
            <source>J Zhejiang Univ Sci B</source>
            <year>2017</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>430</fpage>
            <page-range>430-436</page-range>
            <pub-id pub-id-type="pmid">28471115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mileva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stoilovska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jovanovska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ugrinska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petrushevska</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kostadinova-Kunovska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miladinova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Majstorov</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III.</article-title>
            <source>Radiol Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>27</day>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>370</fpage>
            <page-range>370-376</page-range>
            <pub-id pub-id-type="pmid">30265655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>790</fpage>
            <page-range>790-799</page-range>
            <pub-id pub-id-type="pmid">34376043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitahara</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shiels</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995-2015).</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>112</volume>
            <issue>8</issue>
            <fpage>810</fpage>
            <page-range>810-817</page-range>
            <pub-id pub-id-type="pmid">31638139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Increasing incidence of thyroid cancer in the United States, 1973-2002.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>May</month>
            <day>10</day>
            <volume>295</volume>
            <issue>18</issue>
            <fpage>2164</fpage>
            <page-range>2164-7</page-range>
            <pub-id pub-id-type="pmid">16684987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thyroid cancer.</article-title>
            <source>Epidemiol Prev</source>
            <year>2004</year>
            <season>Mar-Apr</season>
            <volume>28</volume>
            <issue>2 Suppl</issue>
            <fpage>88</fpage>
            <page-range>88-91</page-range>
            <pub-id pub-id-type="pmid">15281612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitahara</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shiels</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>e4823</fpage>
            <page-range>e4823-30</page-range>
            <pub-id pub-id-type="pmid">32984898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arroyo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>KJL</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fernandes-Taylor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alagoz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2022</year>
            <month>Sep</month>
            <day>28</day>
            <volume>107</volume>
            <issue>10</issue>
            <fpage>2945</fpage>
            <page-range>2945-2952</page-range>
            <pub-id pub-id-type="pmid">35947867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krajewska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kukulska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oczko-Wojciechowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kotecka-Blicharz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drosik-Rutowicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haras-Gil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jarzab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Handkiewicz-Junak</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>571421</fpage>
            <pub-id pub-id-type="pmid">33123090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Check</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kitahara</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Apr</month>
            <day>04</day>
            <volume>317</volume>
            <issue>13</issue>
            <fpage>1338</fpage>
            <page-range>1338-1348</page-range>
            <pub-id pub-id-type="pmid">28362912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogucki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buczy&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kr&#x00119;towski</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pop&#x00142;awska-Kita</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Importance of miRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Oct</month>
            <day>15</day>
            <volume>10</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">34682861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Puxeddu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fugazzola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jarzab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Czarniecka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vianello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Riesco-Eizaguirre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santisteban</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sywak</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Clifton-Bligh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bendlova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>S&#x000fd;korov&#x000e1;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2021</year>
            <month>Oct</month>
            <day>21</day>
            <volume>106</volume>
            <issue>11</issue>
            <fpage>3228</fpage>
            <page-range>3228-3238</page-range>
            <pub-id pub-id-type="pmid">34273152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The <italic>BRAF</italic> V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer.</article-title>
            <source>J Cancer</source>
            <year>2020</year>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>932</fpage>
            <page-range>932-939</page-range>
            <pub-id pub-id-type="pmid">31949496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Celik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bulbul</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Ayturk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Durmus</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gurkan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Can</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tastekin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ustun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sezer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guldiken</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.</article-title>
            <source>Med Glas (Zenica)</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-34</page-range>
            <pub-id pub-id-type="pmid">31994851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mendonca-Torres</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gomes-Lima</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wartofsky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bikas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ylli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vasko</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Klubo-Gwiezdzinska</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>02</day>
            <volume>9</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">32748840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Ban</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy.</article-title>
            <source>Head Neck</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-63</page-range>
            <pub-id pub-id-type="pmid">30536465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Brahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Asa</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Papillary thyroid carcinoma: an overview.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>130</volume>
            <issue>7</issue>
            <fpage>1057</fpage>
            <page-range>1057-62</page-range>
            <pub-id pub-id-type="pmid">16831036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma.</article-title>
            <source>Pathol Int</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>11</issue>
            <fpage>605</fpage>
            <page-range>605-613</page-range>
            <pub-id pub-id-type="pmid">30350394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahmat</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kumar Marutha Muthu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S Raja Gopal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jo Han</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yahaya</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Papillary Thyroid Carcinoma as a Lateral Neck Cyst: A Cystic Metastatic Node versus an Ectopic Thyroid Tissue.</article-title>
            <source>Case Rep Endocrinol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>5198297</fpage>
            <pub-id pub-id-type="pmid">30420925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer.</article-title>
            <source>Surgery</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>166</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-60</page-range>
            <pub-id pub-id-type="pmid">30876667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasser</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pitman</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pilch</surname>
                <given-names>BZ</given-names>
              </name>
              <name>
                <surname>Faquin</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Oct</month>
            <day>25</day>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-11</page-range>
            <pub-id pub-id-type="pmid">11038428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krane</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Updates in Thyroid Cytology.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>467</fpage>
            <page-range>467-487</page-range>
            <pub-id pub-id-type="pmid">30190135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bogdanova</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Saenko</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwadate</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogounovitch</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Tronko</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Histopathological analysis of papillary thyroid carcinoma detected during ultrasound screening examinations in Fukushima.</article-title>
            <source>Cancer Sci</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>110</volume>
            <issue>2</issue>
            <fpage>817</fpage>
            <page-range>817-827</page-range>
            <pub-id pub-id-type="pmid">30548366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilmartin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence of Thyroid Cancer among Patients with Thyroid Nodules.</article-title>
            <source>Ir Med J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>10</day>
            <volume>111</volume>
            <issue>8</issue>
            <fpage>802</fpage>
            <pub-id pub-id-type="pmid">30547520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLeod</surname>
                <given-names>DSA</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Durante</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Contemporary Debates in Adult Papillary Thyroid Cancer Management.</article-title>
            <source>Endocr Rev</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1481</fpage>
            <page-range>1481-1499</page-range>
            <pub-id pub-id-type="pmid">31322698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haugen</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>123</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-381</page-range>
            <pub-id pub-id-type="pmid">27741354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Shong</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Active Surveillance for Small Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.</article-title>
            <source>Thyroid</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1399</fpage>
            <page-range>1399-1408</page-range>
            <pub-id pub-id-type="pmid">31368412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coca-Pelaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hernandez-Prera</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ghossein</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hartl</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Shaha</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Zafereo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nixon</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>M&#x000e4;kitie</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Vander Poorten</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sanabria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guntinas-Lichius</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Simo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zb&#x000e4;ren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Angelos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Khafif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rinaldo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferlito</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>3112</fpage>
            <page-range>3112-3128</page-range>
            <pub-id pub-id-type="pmid">32488657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>I&#x000f1;iguez-Ariza</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Management of Low-Risk Papillary Thyroid Cancer.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-194</page-range>
            <pub-id pub-id-type="pmid">29947175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawka</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ghai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoannidis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rotstein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gullane</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Eskander</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Irish</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Enepekides</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gooden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zahedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ezzat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rac</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stanimirovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gafni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer.</article-title>
            <source>Thyroid</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>999</fpage>
            <page-range>999-1007</page-range>
            <pub-id pub-id-type="pmid">32126932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Timsina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Angelos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Haggstrom</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Changes in total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer during the past 15 years.</article-title>
            <source>Surgery</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>166</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-47</page-range>
            <pub-id pub-id-type="pmid">30904172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vargas-Pinto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Romero Arenas</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Lobectomy Compared to Total Thyroidectomy for Low-Risk Papillary Thyroid Cancer: A Systematic Review.</article-title>
            <source>J Surg Res</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>242</volume>
            <fpage>244</fpage>
            <page-range>244-251</page-range>
            <pub-id pub-id-type="pmid">31103828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gartland</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lubitz</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Impact of Extent of Surgery on Tumor Recurrence and Survival for Papillary Thyroid Cancer Patients.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>2520</fpage>
            <page-range>2520-2525</page-range>
            <pub-id pub-id-type="pmid">29855833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER.</article-title>
            <source>Onco Targets Ther</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>3551</fpage>
            <page-range>3551-3560</page-range>
            <pub-id pub-id-type="pmid">29950860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Thermal Ablation for Small Papillary Thyroid Cancer: A Systematic Review.</article-title>
            <source>Thyroid</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>12</issue>
            <fpage>1774</fpage>
            <page-range>1774-1783</page-range>
            <pub-id pub-id-type="pmid">31739738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.</article-title>
            <source>Eur Radiol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>4897</fpage>
            <page-range>4897-4903</page-range>
            <pub-id pub-id-type="pmid">30805701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallahi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Galdiero</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Varricchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ragusa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paparo</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Benvenga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Molecular targets of tyrosine kinase inhibitors in thyroid cancer.</article-title>
            <source>Semin Cancer Biol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>79</volume>
            <fpage>180</fpage>
            <page-range>180-196</page-range>
            <pub-id pub-id-type="pmid">33249201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koehler</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pfestroff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kutsch</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lapa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sandner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rayes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fuss</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Kreissl</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allelein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Todica</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fassnacht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kroiss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spitzweg</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.</article-title>
            <source>Thyroid</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>1531</fpage>
            <page-range>1531-1541</page-range>
            <pub-id pub-id-type="pmid">34405734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wuest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez-Campistrous</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glubrecht</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jans</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Wuest</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McMullen</surname>
                <given-names>TPW</given-names>
              </name>
            </person-group>
            <article-title>Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>495</fpage>
            <page-range>495-507</page-range>
            <pub-id pub-id-type="pmid">32590338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LiVolsi</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Merino</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Worrisome histologic alterations following fine-needle aspiration of the thyroid (WHAFFT).</article-title>
            <source>Pathol Annu</source>
            <year>1994</year>
            <volume>29 ( Pt 2)</volume>
            <fpage>99</fpage>
            <page-range>99-120</page-range>
            <pub-id pub-id-type="pmid">7936753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baloch</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>LiVolsi</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Fine-needle aspiration of thyroid nodules: past, present, and future.</article-title>
            <source>Endocr Pract</source>
            <year>2004</year>
            <season>May-Jun</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-41</page-range>
            <pub-id pub-id-type="pmid">15310542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bresee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Braunstein</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma.</article-title>
            <source>Thyroid</source>
            <year>2013</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-74</page-range>
            <pub-id pub-id-type="pmid">23106409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loh</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Greenspan</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Gee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>82</volume>
            <issue>11</issue>
            <fpage>3553</fpage>
            <page-range>3553-62</page-range>
            <pub-id pub-id-type="pmid">9360506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higashiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients.</article-title>
            <source>World J Surg</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>615</fpage>
            <page-range>615-622</page-range>
            <pub-id pub-id-type="pmid">29349484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ulisse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lauro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pironi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tripodi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferent</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Amabile</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Catania</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Matteo</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Forte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sorrenti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Papillary Thyroid Cancer Prognosis: An Evolving Field.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Nov</month>
            <day>07</day>
            <volume>13</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">34771729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vuong</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>TTB</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hassell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kakudo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.</article-title>
            <source>Pathol Res Pract</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>240</volume>
            <fpage>154180</fpage>
            <pub-id pub-id-type="pmid">36306725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer.</article-title>
            <source>Aging (Albany NY)</source>
            <year>2019</year>
            <month>Jan</month>
            <day>20</day>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>480</fpage>
            <page-range>480-500</page-range>
            <pub-id pub-id-type="pmid">30661062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzaferri</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Jhiang</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</article-title>
            <source>Am J Med</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>418</fpage>
            <page-range>418-28</page-range>
            <pub-id pub-id-type="pmid">7977430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeGroot</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Natural history, treatment, and course of papillary thyroid carcinoma.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>414</fpage>
            <page-range>414-24</page-range>
            <pub-id pub-id-type="pmid">2380337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30159.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sebastian</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Paricio</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Flores</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Madrona</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Tebar</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Papillary thyroid carcinoma: prognostic index for survival including the histological variety.</article-title>
            <source>Arch Surg</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>135</volume>
            <issue>3</issue>
            <fpage>272</fpage>
            <page-range>272-7</page-range>
            <pub-id pub-id-type="pmid">10722027</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
